ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance is stable with positive revenue growth and a solid cash balance. However, challenges exist in regulatory and coverage hurdles, and SG&A expenses are high. The Q&A reveals some concerns about inventory dynamics and the unclear timeline for unrestricted access. Despite strategic initiatives and global expansion plans, the overall sentiment remains neutral due to the lack of immediate catalysts and ongoing uncertainties in coverage and market expansion.
Key Financial Performance
Net Product Revenue $72.2 million for the first full year of commercial sales, reflecting meaningful physician engagement and patient uptake. Growth was influenced by structural dynamics of the category, such as refill dominance, electronic prescribing patterns, prior authorization requirements, and seasonal factors like deductible resets and back-to-school demand.
Total Revenue $84.3 million for the full year 2025, comprised of $72.2 million in U.S. net product revenue, $9.7 million from collaboration agreements, and $2.4 million in supply revenue from international partners. This reflects the first full year of commercial sales and collaboration activities.
R&D Expenses $13.2 million, primarily driven by product development, clinical trials, and personnel-related costs.
SG&A Expenses $230.1 million, reflecting investments in commercialization, including DTC campaigns and sales team expansion. These investments were strategic to build durable market share and long-term brand equity.
Gross to Net Retention In the low to mid-50% range at year-end 2025, with a target of around 50% at steady state. Improvements are expected as coverage broadens and prior authorization requirements decline.
Cash Balance $245 million in cash, cash equivalents, and short-term investments at year-end 2025, sufficient to fund ongoing commercial expansion, DTC investments, and the chronic spontaneous urticaria program through expected cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Neffy: Neffy is the only FDA-approved needle-free treatment for type 1 allergic reactions, including anaphylaxis. Real-world data shows approximately 90% of patients are effectively treated with a single dose. Generated $72.2 million in net product revenue in its first full year of commercial sales.
International Expansion: Regulatory approvals secured across Europe, China, Japan, and Australia. Partner-led launches expected in 2026.
Sales Force Expansion: Sales force to expand from 106 to 150 representatives in 2026, funded through reallocation of existing resources without increasing SG&A expenses.
Digital Strategy: Strengthened virtual and digital strategy with the Get neffy on Us program, offering free virtual visits and zero co-pay for eligible patients. Early engagement indicators are encouraging.
Market Access: Ended 2025 with 93% commercial coverage, with 57% of covered lives having access without prior authorization. Focused on reducing prior authorization requirements and expanding unrestricted coverage.
Pipeline Development: Advancing pipeline for chronic spontaneous urticaria flares with interim data expected in the second half of 2026 and Phase III trials beginning in mid-2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Structure Challenges: Growth has not followed a linear trajectory due to the structural dynamics of the mature refill-driven market, including refill dominance, electronic prescribing patterns, and prior authorization requirements.
New Entrant Friction: As a new product, neffy faces challenges such as reliance on new prescriptions requiring office visits, education, workflow adoption, and administrative time, which introduce friction early in the launch.
Prior Authorization Requirements: Approximately 43% of covered lives still require prior authorization, creating administrative friction and dampening prescribing momentum in a high-volume category.
Competitive Market Dynamics: Legacy auto-injectors benefit from decades of embedded renewal behavior within physician workflows, making it challenging for neffy to gain market share.
Operational Execution: The need for consistent engagement with high-volume accounts (at least 3 calls per month) and the expansion of the sales force to improve execution intensity highlight operational challenges.
Consumer Conversion Challenges: While awareness has increased, prescription conversion is influenced by factors such as ad frequency, appointment timing, product access, and payer coverage, which remain barriers to growth.
Medicaid Coverage Barriers: In some states, Medicaid coverage requires prior authorization, creating additional hurdles for healthcare providers and patients.
Renewal Workflow Integration: Embedding neffy into electronic renewal workflows is critical to intercept patients at the point of renewal, but this remains a work in progress.
Cash Flow and Financial Discipline: The company is reliant on disciplined capital allocation and cost optimization to fund commercial expansion and achieve cash flow breakeven, which could be impacted by unforeseen financial pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales Force Expansion: The company plans to expand its sales force from 106 to 150 representatives in the second quarter of 2026 to increase engagement with priority accounts. This expansion will be funded through reallocation of existing commercial resources, ensuring no increase in SG&A expenses for 2026.
Market Access and Coverage: The company aims to expand unrestricted coverage with CVS Caremark and other major payers. Currently, 93% of commercial coverage is achieved, with 57% of covered lives having access without prior authorization. Efforts are ongoing to reduce prior authorization requirements to improve prescribing momentum.
Renewal Dynamics: The company expects renewal contributions to become increasingly relevant beginning later in 2026 and into 2027 as the installed patient base matures and product reaches expiration cycles.
International Expansion: Regulatory approvals and partner-led launches are expected across Europe, China, Japan, and Australia in 2026, reinforcing the global opportunity for neffy.
Pipeline Development: Interim data from the Phase IIb trial for the treatment of chronic spontaneous urticaria flares is expected in the second half of 2026, with the study completion targeted by the end of 2026 and Phase III beginning in mid-2027.
Digital and Virtual Strategy: The company is strengthening its digital strategy, including the Get neffy on Us program, which offers free virtual visits and zero co-pay for eligible patients. This program is expected to expand meaningfully over the next 12 months as awareness grows.
DTC Campaign Evolution: The direct-to-consumer campaign has been refreshed to emphasize practical real-world use and emotional benefits, aiming to increase awareness and prescription conversion over the next 12 to 18 months.
Financial Discipline: The company plans to optimize spending by reallocating resources to high-return commercial execution areas, maintaining a neutral SG&A expense run rate in 2026 while accelerating revenue growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are you thinking about inventory dynamics in 1Q and into the 2Q back-to-school ramp?
A:Eric Karas stated that they are closely monitoring 'days on hand' and are comfortable with the current inventory dynamics in 1Q. They will continue to watch closely during the June-September back-to-school season as share and volume increase.
Q:How are you looking at the direct-to-consumer spend in 2026?
A:Richard Lowenthal mentioned that the direct-to-consumer spend in 2026 is expected to be similar to 2025, approximately $100 million, including direct-to-health care provider advertising.
Q:Can you give more color on the contribution from the Get neffy program and timing on expanding unrestricted access?
A:Richard Lowenthal noted that over 10% of prescriptions are coming through getneffy.com, and the program is growing well. Regarding unrestricted access, they expect substantial expansion by summer, with Caremark implementing changes by July 1 and other insurers potentially moving faster. They are also making progress on Medicaid coverage.
Q:Where is the funding for the sales force expansion coming from, and what is being deprioritized?
A:Richard Lowenthal and Eric Karas explained that funding is being reallocated from advertising, market research, large conferences, and some media spending. They emphasized that these changes will not impact their ability to execute their goals.
Q:What are you seeing from the direct-to-consumer campaign beyond awareness?
A:Richard Lowenthal and Eric Karas highlighted that they can track patient behavior from watching commercials to getting prescriptions. Surveys show strong recall of advertisements (mid-to-upper 50s), and the campaign's messages about ease of use and emotional impact are resonating well.
Q:How should we think about the timing and cadence of refills and the proportion of new scripts versus refills by year-end?
A:Richard Lowenthal and Eric Karas stated that refill dynamics will pick up meaningfully by the end of the year, with some increase over the summer due to back-to-school needs. Currently, the majority of prescriptions are new, with 75% coming from patients with needle injectors and 25% from other audiences.
Q:How should we think about SG&A spend throughout the year with the new advertising campaign?
A:Richard Lowenthal mentioned that SG&A spend will remain consistent, with no anticipated changes due to the new campaign, which focuses on updated messaging and creative aspects.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about the funding sources for the sales force expansion. While they mentioned reallocating from advertising, market research, and conferences, the response lacked specific details on the exact budgetary adjustments or amounts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DTC conversion
Medicaid
adoption field
advancement
authorization requirement
awareness prescription
base matures
behavior
brand equity
consistency
coverage plan
decision renewal
dominance
dynamic
expansion
friction
integration
learning
lifestyle
objective
office visit
pathway
patient base
plan authorization
prescriber adoption
prescription conversion
priority account
product market
reallocation resource
refill decision
refill prescription
renewal workflow
state
territory
volume category
volume practice
SPRY Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects a positive outlook with strategic expansions, improved payer access, and a strong international presence. Despite some lack of clarity in management's responses, there is confidence in achieving breakeven by mid-2027 and significant market share growth. The absence of a market cap suggests a potential strong reaction, but overall, the strategic initiatives and positive guidance point to a likely positive stock price movement in the short term.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed outlook. Financial performance is stable with positive revenue growth and a solid cash balance. However, challenges exist in regulatory and coverage hurdles, and SG&A expenses are high. The Q&A reveals some concerns about inventory dynamics and the unclear timeline for unrestricted access. Despite strategic initiatives and global expansion plans, the overall sentiment remains neutral due to the lack of immediate catalysts and ongoing uncertainties in coverage and market expansion.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Positive11-10
The company reported strong growth in neffy prescriptions and revenue, with a 2.5-fold increase in U.S. net product revenue. Despite a net loss, the financial health remains stable with significant cash reserves. The Q&A highlighted positive feedback from new initiatives and optimism about future growth through partnerships and expanded market access. While some uncertainties exist, such as reliance on a term loan and inconsistent institutional sales, the overall sentiment is positive due to revenue growth, strategic initiatives, and optimistic guidance.
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A indicate strong growth in Neffy's sales and positive market reception, demonstrated by a 64% increase in revenue and increased prescriptions. The DTC campaign is expected to further drive growth. However, there is some concern about the ceiling for commercial coverage without prior authorization. Despite this, the overall sentiment is positive due to strong financial performance and optimistic future guidance.
SPRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
